Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer by Jacobsen, Kirstine et al.
Syddansk Universitet
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Jacobsen, Kirstine; Bertran-Alamillo, Jordi; Molina, Miguel Angel; Teixidó, Cristina;
Karachaliou, Niki; Pedersen, Martin Haar; Castellví, Josep; Garzón, Mónica; Codony-Servat,
Carles; Codony-Servat, Jordi; Giménez-Capitán, Ana; Drozdowskyj, Ana; Viteri, Santiago;
Larsen, Martin Røssel; Lassen, Ulrik; Felip, Enriqueta; Bivona, Trever G; Ditzel, Henrik;
Rosell, Rafael
Published in:
Nature communications
DOI:
10.1038/s41467-017-00450-6
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Jacobsen, K., Bertran-Alamillo, J., Molina, M. A., Teixidó, C., Karachaliou, N., Pedersen, M. H., ... Rosell, R.
(2017). Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature
communications, 8, [410]. DOI: 10.1038/s41467-017-00450-6
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 15. Oct. 2017
ARTICLE
Convergent Akt activation drives acquired EGFR
inhibitor resistance in lung cancer
Kirstine Jacobsen1, Jordi Bertran-Alamillo2, Miguel Angel Molina2, Cristina Teixidó2, Niki Karachaliou3,
Martin Haar Pedersen1, Josep Castellví2, Mónica Garzón2, Carles Codony-Servat2, Jordi Codony-Servat2,
Ana Giménez-Capitán2, Ana Drozdowskyj4, Santiago Viteri5, Martin R. Larsen6, Ulrik Lassen7, Enriqueta Felip8,
Trever G. Bivona9,10, Henrik J. Ditzel 1,11 & Rafael Rosell2,5,12,13
Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR)
mutations typically beneﬁt from EGFR tyrosine kinase inhibitor treatment. However, virtually
all patients succumb to acquired EGFR tyrosine kinase inhibitor resistance that occurs via
diverse mechanisms. The diversity and unpredictability of EGFR tyrosine kinase inhibitor
resistance mechanisms presents a challenge for developing new treatments to overcome
EGFR tyrosine kinase inhibitor resistance. Here, we show that Akt activation is a convergent
feature of acquired EGFR tyrosine kinase inhibitor resistance, across a spectrum of diverse,
established upstream resistance mechanisms. Combined treatment with an EGFR tyrosine
kinase inhibitor and Akt inhibitor causes apoptosis and synergistic growth inhibition in
multiple EGFR tyrosine kinase inhibitor-resistant non-small-cell lung cancer models. More-
over, phospho-Akt levels are increased in most clinical specimens obtained from EGFR-
mutant non-small-cell lung cancer patients with acquired EGFR tyrosine kinase inhibitor
resistance. Our ﬁndings provide a rationale for clinical trials testing Akt and EGFR inhibitor
co-treatment in patients with elevated phospho-Akt levels to therapeutically combat the
heterogeneity of EGFR tyrosine kinase inhibitor resistance mechanisms.
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Lung cancer is the leading cause of cancer mortalityworldwide1. Mutations in epidermal growth factor receptor(EGFR), most commonly deletions in exon 19 (delE746-750)
or substitution of arginine for leucine (L858R) in exon 21, are
present in ~17% of tumors in patients with pulmonary adeno-
carcinoma2 and confer sensitivity to the EGFR-tyrosine kinase
inhibitors (TKIs) geﬁtinib3, 4, erlotinib5, 6 or afatinib7, 8. The
principal downstream pathways mediating the oncogenic effects
of EGFR are extracellular signal–regulated kinase 1 and 2 (ERK1/
2) via Ras, Akt via phosphatidylinositol 3-kinase (PI3K), and
signal transducer and activator of transcription 3 (STAT3) via
Janus kinase 2 (JAK2)9.
Acquired resistance substantially limits the clinical efﬁcacy of
EGFR TKIs. Although ~70% of EGFR-mutant non-small-cell
lung cancer (NSCLC) patients respond to ﬁrst-line EGFR-TKI
treatment, the majority of them do not achieve complete
responses and virtually all patients develop acquired resistance
and lethal disease progression6. A diversity of EGFR-TKI
resistance mechanisms has been described, of which the most
frequent mechanism of resistance to EGFR-TKI treatment is the
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Fig. 1 Expression of proteins related to acquired resistance in parental and resistant PC9 cell lines. a Immunohistochemistry of selected EMT markers. Scale
bar, 100 µm. b Relative mRNA expression of selected genes. Experiments were performed in triplicates and results are shown as mean± SD. Asterisks
indicate signiﬁcant difference from PC9 in a Student’s t-test. c Western blot analysis of selected proteins. In all cases, PC9 cells were grown without drug,
whereas PC9-GR1-5 were grown in 5 µM geﬁtinib and PC9-ER was grown in 30 µM erlotinib
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00450-6
2 NATURE COMMUNICATIONS |8:  410 |DOI: 10.1038/s41467-017-00450-6 |www.nature.com/naturecommunications
secondary mutation in exon 20 of EGFR, T790M10, 11. Other
mechanisms include ampliﬁcation, overexpression, and autocrine
loops involving MET proto-oncogene (MET), erb-b2 receptor
tyrosine kinase 2 (ErbB2), ephrin type-A receptor 2 (EphA2),
ﬁbroblast growth factor receptor (FGFR) and the members of
the TAM receptor tyrosine kinase (RTKs), Mer and AXL12–15.
In addition, we have shown that activation of NF-κB rescues
EGFR-mutant lung cancer cells from EGFR-TKI treatment16.
Finally, BRAF and PIK3CA mutations, conversion to small-cell-
lung cancer and occurrence of epithelial-to-mesenchymal
transition (EMT) have also been associated with acquired
resistance to EGFR-TKI in NSCLC12. Certain EGFR-mutant
NSCLCs harbor multiple mechanisms of EGFR-TKI resistance17, 18.
In these cases, the co-occurrence of multiple resistance mechan-
isms is likely to lessen the therapeutic impact of targeting each
individual resistance-promoting alteration. Additionally, which
speciﬁc resistance alteration(s) will arise and promote EGFR-TKI
resistance in individual patients is currently largely unpredictable
at the outset of therapy. Hence, the diversity and unpredictability
of EGFR-TKI resistance mechanisms presents a major challenge
for efﬁciently developing new treatment regimens that can
overcome EGFR-TKI resistance in patients.
Activation of the Akt pathway is a common feature in
human cancers and leads to increased cell survival, growth, and
proliferation19. V-akt murine thymoma viral oncogene homologs
1, 2 and 3 (Akt1, Akt2, and Akt3) comprise the Akt family of
serine-threonine kinases, which are tethered to the membrane via
interaction with phosphatidylinositol-3,4,5-triphosphate (PIP3)
lipids20, and activated by phosphorylation on threonine 308
(Thr308) by 3-phosphoinositide-dependent protein kinase 1
(PDK1)21 and serine 473 (Ser473) by the mammalian target
of rapamycin complex 2 (mTORC2)22. Activated Akt
phosphorylates many downstream targets, including forkhead
box O3 (FOXO3) and proline-rich Akt substrate of 40 kDa
(PRAS40)23–26. Several small molecule drugs targeting
components of the Akt pathway have been developed and are
being tested in patients27. Interestingly, ﬁrst-line sensitivity to
EGFR TKIs in NSCLC has been associated with pre-existent Akt
activation that is suppressed by EGFR inhibition, while treatment
with EGFR TKIs failed to block Akt signaling in tumor cells
intrinsically resistant to these drugs28–31. In addition, the
combination of a PIK3-mTOR inhibitor with a MEK inhibitor
has been reported to induce apoptosis in EGFR-TKI naïve
EGFR-mutant NSCLC cell lines and xenografts, although the
combination of an Akt and a MEK inhibitor failed to have this
effect in this TKI-naive context32. Despite evidence suggesting
a general role for PI3K-AKT-mTOR pathway signaling in
EGFR-mutant NSCLC, whether Akt activation, speciﬁcally, can
drive acquired EGFR-TKI resistance has not been clearly
demonstrated. Furthermore, the hypothesis that Akt activation
functions as a convergent, resistance-driving signaling
event across a spectrum of EGFR-mutant NSCLCs that harbor
otherwise diverse, established EGFR-TKI resistance-promoting
mechanisms has not been tested.
Here, we show that Akt pathway activation is a convergent
feature in EGFR-mutant NSCLCs with acquired resistance
to EGFR TKIs that may be caused by diverse underlying
mechanisms. This convergent resistance-promoting function of
Akt activation occurred in the presence of one or more
different resistance mechanisms such as ampliﬁcation,
overexpression, and activation of MET, EphA2, FGFR, Mer, and
AXL or the presence of the T790M mutation. We show that
combined treatment with Akt and EGFR inhibitors in resistant
EGFR-mutant NSCLC models synergistically inhibits growth in
this heterogeneous molecular background. We also show that
phospho-Akt (pAkt) is increased in the majority of EGFR-mutant
patients after progression on EGFR TKIs, and also that high levels
of pAkt in patients prior to EGFR-TKI treatment correlates with
poor initial therapeutic responses. Thus, convergent Akt activa-
tion is a previously unrecognized therapeutic target whose inhi-
bition has the unique potential to combat the profound molecular
heterogeneity underlying EGFR-TKI clinical resistance. Our
ﬁndings provide a new rationale to test combined Akt plus EGFR
inhibitor treatment, speciﬁcally in EGFR-mutant NSCLCs with
high pAkt levels, to overcome acquired EGFR-TKI resistance and
enhance patient survival.
Results
Establishment of PC9-derived cell lines resistant to EGFR
TKIs. Six EGFR-TKI-resistant cell lines were generated by
treating EGFR-TKI-sensitive PC9 cells, which harbor the EGFR
exon 19 deletion, with increasing concentrations of geﬁtinib
(GR1-5) or erlotinib (ER). Sequencing analyses revealed that all
six cell lines retained the EGFR exon 19 deletion (Supplementary
Table 1), while the T790M mutation emerged in two (PC9-GR1
and PC9-GR4 at allelic fractions of 25 and 38% respectively).
No mutations were detected in HER2, PIK3CA, BRAF of KRAS.
We determined the sensitivity of the parental and resistant cell
lines to a variety of EGFR TKIs (Supplementary Table 2). The
half-maximal inhibitory concentration (IC50) for geﬁtinib
and erlotinib of parental PC9 cells was in the nanomolar
range compared to 4–29 µM in the resistant cell lines. In T790M-
negative cells (PC9-ER, -GR2, -GR3, and -GR5), acquisition
of resistance to EGFR-TKI also led to insensitivity to the second-
(afatinib or dacomitinib) and third- (osimertinib (AZD9291))
generation EGFR TKIs. The T790M-positive cell lines (PC9-GR1
and -GR4) remained sensitive to osimertinib and became only
moderately resistant to afatinib and dacomitinib. Acquisition of
the resistant phenotype was often associated with morphological
changes and altered anchorage-independent growth, invasiveness,
and migration (Supplementary Fig. 1).
Common resistance mechanisms in PC9-derived cell lines.
To delineate the underlying resistance mechanism of the
EGFR-TKI-resistant cell lines, we initially investigated previously
reported acquired resistance mechanisms other than T790M
mutation using ﬂuorescence in situ hybridization, immunohis-
tochemistry (IHC), quantitative real-time polymerase chain
reaction (qRT-PCR) and wsestern blotting. Regarding mRNA and
protein expression, AXL upregulation was the most common
molecular event, while FGFR1 overexpression and EphA2 and
MET activation were also found in some of the resistant cell
lines (Figs. 1a–c). In contrast, no signiﬁcant differences were
observed in the case of FGFR2, MER (Figs. 1b, c), ErbB2, or
ErbB3 (Supplementary Fig. 2). Alterations in proteins related to
apoptosis (Bcl-2, Bcl-xl, and BIM) and EMT (E-cadherin,
vimentin, N-cadherin, and beta-catenin) were also observed
(Figs. 1a, c). EGFR was equally ampliﬁed in the parental PC9 and
all the resistant cell lines, while there was no MET, FGFR1, or
ErbB2 ampliﬁcation in any of them. In all six resistant cell lines,
two or more possible mechanisms of acquired resistance were
simultaneously present (Supplementary Table 3), but each cell
line had a unique proﬁle in terms of the speciﬁc repertoire of
established resistance mechanisms.
Quantitative proteomic analysis of PC9-ER resistant cells.
To further identify mechanisms associated with EGFR-TKI
resistance, we used quantitative proteomics to compare the
proteomes of parental and PC9-ER cells. To increase the number
of proteins identiﬁed, samples were ﬁrst separated into soluble
and membrane-associated proteins and subsequently fractionated
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by hydrophilic interaction liquid chromatography (HILIC). Each
of the ten HILIC fractions was subsequently analyzed by liquid
chromatography tandem mass spectrometry (LC–MS/MS). PC9
and PC9-ER cells were analyzed in biological triplicates. A total of
3535 proteins were identiﬁed based on two unique peptides (FDR
1%) with an overlap of 63.5% between the membrane-associated
and soluble fractions. Based on the distribution of the log2
transformed ratios of differentially expressed proteins, 2-fold was
chosen as the differential expression threshold. A total of 357
proteins exhibited altered expression, of which 247 were
upregulated and 110 downregulated, in the EGFR-TKI-resistant
PC9-ER cells compared to the EGFR-TKI-sensitive, parental
PC9 cells.
Next, the differentially expressed proteins between EGFR-TKI-
sensitive and -resistant cells were classiﬁed according to functional
subgroups (Supplementary Fig. 3a–c). The extensive number of
proteins differentially expressed and the variety of cell processes
affected revealed an entire reprogramming of the cell machinery
associated with the emergence of resistance. Four membrane
receptors were upregulated in the resistant cell lines: AXL,
integrin alpha-V (ITGAV) and, to a lesser extent, insulin-like
growth factor 2 receptor and EGFR. The result for AXL was
coincident with the upregulation shown by western blotting, IHC
and qRT-PCR. Regarding intracellular signal transduction, the
most relevant ﬁnding was the 7-fold upregulation of the
mammalian target of rapamycin (mTOR). We also observed a
signiﬁcant overexpression of key proteins such as v-crk avian
sarcoma virus CT10 oncogene homolog-like (CRKL), ERK1,
ERK2, several G-proteins and GTPase activators, some phospha-
tases and the ubiquitin E3 ligase Midline 1 (MID1; Fig. 2a).
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The roles of mTOR, ERK1 and ERK2 are widely known, while
CRKL is an oncogene that constitutes a major convergence point
in tyrosine kinase signaling. In addition, CRKL ampliﬁcation has
been described as a mechanism of acquired resistance to EGFR
TKIs in some EGFR-mutant NSCLCs, acting via activation of the
ERK and Akt pathways33. MID1 is known to activate the Akt/
b
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Fig. 3 Synergistic effects of EGFR TKIs combined with Akt inhibitors in parental and EGFR-TKI-resistant PC9 cells. The combined effects of EGFR inhibitors
(erlotinib for PC9-ER and geﬁtinib for parental PC9 and PC9-GR1-5) and Akt inhibitors (GSK2141795 or AZD5363 for all cell lines) were assessed by a
crystal violet viability assay performed over 8 days, b BrdU incorporation assay performed after 48 and 96 h incubation, and c apoptosis assay performed
after 96 h incubation. Concentrations of drugs were chosen to be sub-inhibitory to explore the synergistic potential: erlotinib 30 µM; geﬁtinib 5 µM (except
for PC9 where 40 nM was used); GSK2141795 (G) 2.5 µM; AZD5363 (A) 35 µM, (except for GR2 and GR5 where 1.25 and 3 µM were employed). All
experiments were conducted in quadruplicates (a), or triplicates (b, c), and results are shown as mean± SD. Asterisks indicate signiﬁcant difference in
ANOVA one-way test (p< 0.05) for the drug combination-treated cells compared to cells treated with either drug alone at the same time point
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mTOR pathway through degradation of the catalytic subunit of
the tumor suppressor phosphatase 2A (PP2A)34.
We subsequently performed a global analysis of the selected
proteins using the Ingenuity Pathway Analysis software.
Regarding signal transduction, the most relevant ﬁnding was
the upregulation of the PI3K-Akt-mTOR signaling pathway in
the EGFR-TKI-resistant vs. sensitive cells. This ﬁnding was
in agreement with the upregulation of several proteins involved in
or activated by the PI3K-Akt-mTOR signaling pathway revealed
by the individual analyses, such as the membrane receptors AXL,
ITGAV, and IGFR2, the downstream signaling proteins CRKL
and mTOR, the ubiquitin ligase MID1 or the lysine oxidase
LOXL2 (Fig. 2a).
Activation of the Akt pathway in PC9-derived resistant cell
lines. In view of the proteomics results, we explored the activation
status of Akt signal transduction pathways in the parental and
resistant cell lines (Fig. 2b) and also studied ERK and STAT3
activation. The levels of pAkt and its downstream effector
phospho-PRAS40 (pPRAS40) were elevated in the presence of
EGFR TKI in all the resistant cell lines, regardless of T790M,
AXL, MET, EphA2, or FGFR1 status, while signiﬁcant levels
pFOXO1/3a were also present, indicating that Akt is a convergent
hub for a variety of acquired resistance mechanisms. In contrast,
key effector proteins of ERK and STAT3 signaling pathways
did not show the same consistent behavior (Fig. 2b). The two
resistant T790M-positive cell lines had increased levels of
phospho-ERK (pERK) in the presence of EGFR-TKI,
while ERK activation was strongly inhibited by the drug in
T790M-negative cell lines. Finally, phosphorylated levels of
STAT3 and c-Src were only elevated in one and three resistant
cell lines, respectively.
To gain insight in the mechanisms leading to Akt activation,
resistant cells were treated with selected targeted agents
(Supplementary Fig. 4). The FGFR inhibitor nintedanib and the
MET inhibitor crizotinib induced a dose-dependent decrease of
pAkt levels in PC9-GR5 and PC9-GR2, respectively. PC9-GR5
cells overexpress FGFR1 and PC9-GR2 cells show MET activation
(Fig. 1b). In contrast, the AXL inhibitor BGB324 had little or
no effect on Akt phosphorylation when added to the
AXL-overexpressing PC9-ER cells. Finally, the T790M-positive
PC9-GR1 cells, which also show MET activation, were
treated with crizotinib and osimertinib. Both drugs induced a
moderate, dose-dependent decrease in pAKT levels (Supplemen-
tary Fig. 4d).
EGFR TKI and an Akt inhibitor elicits synergistic growth
inhibition. Of all the RTKs and signal transduction proteins
investigated, only Akt and PRAS40 were consistently activated
in the six resistant cell lines in the presence of EGFR TKI.
Consequently, we assessed the effects of two different Akt
inhibitors, GSK2141795 and AZD5363, on cell growth and
signaling. When tested as single agents, both inhibited cell growth
with IC50s of 5–15 µM (Supplementary Fig. 5a). When combined
with an EGFR TKI, the Akt inhibitors elicited a synergistic
growth inhibitory effect on the six resistant cell lines, which
was signiﬁcantly less strong in the parental PC9 (Fig. 3a, b and
Supplementary Table 4). This synergistic effect was observed at
all incubation times tested and with a variety of methods:
including crystal violet, measuring the number of cells (Fig. 3a),
CellTiterBlue, estimating the metabolic activity of living cells
(Supplementary Fig. 5b) and BrdU incorporation, measuring cell
proliferation (Fig. 3b). Finally, addition of an Akt inhibitor to the
EGFR TKI also had a signiﬁcant enhancing effect on apoptosis as
measured by a DNA fragmentation assay (Fig. 3c). In view of
these results, we examined the effects of the Akt inhibitors and
EGFR-TKI treatment on signal transduction pathways in three
cell lines: PC9, PC9-ER (T790M-negative) and PC9-GR1
(T790M-positive; Fig. 4a–c). EGFR TKIs alone suppressed
phospho-EGFR (pEGFR), and pERK to a lesser extent, while
having little or no effect on activation of Akt (S473) and its
downstream effectors PRAS40 and FOXO1/3 A. Conversely, Akt
inhibitors did not modify phosphorylation levels of EGFR or
ERK, but signiﬁcantly decreased Akt pathway activation.
Both GSK2141795 and AZD5363 completely blocked PRAS40
phosphorylation, while only AZD5363 suppressed FOXO1/3A
activation in the resistant cell lines. Both inhibitors
caused increased Akt phosphorylation in all cell lines, as shown
previously35, 36, but the reduced phosphorylation levels of
PRAS40 and FOXO1/3A clearly indicated inhibition of Akt
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kinase activity. Combining an EGFR TKI with either
GSK2141795 or AZD5363 resulted in simultaneous inhibition
of EGFR, PRAS40 and FOXO1/3A phosphorylation (Fig. 4a–c).
We also considered other targets of the Akt pathway and included
a PI3K-mTOR inhibitor, GSK2141458, to be combined
with EGFR inhibitors (Supplementary Fig. 5c). However, less
synergism was observed with the PI3K-mTOR inhibitor com-
pared to the Akt inhibitor GSK2141795 in combination with an
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Fig. 5 Expression of selected proteins in parental and resistant 11–18 cells and synergistic effects of EGFR TKIs and Akt inhibitors. a Relative mRNA
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EGFR inhibitor, indicating that Akt inhibition may be the most
effective strategy for blocking the pathway and survival in these
cells (Supplementary Table 5).
Activation of Akt in 11–18-derived EGFR-TKI-resistant cell
lines. To validate our ﬁndings in an additional and independent
system, we generated and characterized six other EGFR-TKI-
resistant cell lines derived from the 11–18 NSCLC cell line,
which harbors the other major EGFR-TKI-sensitizing EGFR
mutation observed in NSCLC patients, EGFR L858R. The IC50s
for geﬁtinib were 40–200-fold higher in the EGFR-TKI-resistant,
derivative sub-lines (11–18 GR1-GR6), all of which retained the
L858R mutation (Supplementary Table 6). The T790M mutation
did not appear in any of the resistant cell lines. The resistant cell
lines were morphologically different from the 11–18 parental
cells, with four exhibiting a fusiform appearance (Supplementary
Fig. 6). No MET ampliﬁcation was detected in any of the
cell lines. Protein and gene expression analyses revealed AXL
upregulation in one, upregulation of FGFR1, MET, and Mer in
some, and upregulation of EGFR in all of the 11–18 resistant cells
(Fig. 5a and Supplementary Fig. 5). HER2 and HER3 levels
were not elevated in the resistant cell lines compared to 11–18
(Supplementary Fig. 5). Low levels of pEGFR were observed in
the presence of geﬁtinib in all cases. Accordingly, signiﬁcant levels
of pERK and pSrc were also observed in most of them (Fig. 5b).
Finally, high E-cadherin and beta-catenin expression levels were
revealed in the parental cells and were only slightly reduced in the
resistant clones. Vimentin expression levels were low in the
parental and the resistant cells and no N-cadherin expression was
detected in any of the cells (Supplementary Fig. 6a). In conclu-
sion, resistance mechanisms in the 11–18 cells were diverse and
differed from those in the PC9 model. No T790M mutations or
indication of EMT were detected, and only one cell line showed
AXL overexpression, while EGFR was upregulated in all cases.
Consequently, while EGFR TKIs completely inactivated the
EGFR/ERK pathway in T790M-negative resistant cells derived
from PC9, they failed to block activation of ERK and did not
completely inhibit EGFR phosphorylation in ﬁve of the six
resistant cell lines derived from 11–18 cells. Remarkably,
increased activation of the Akt pathway was found to be the only
common trait between the total of eleven resistant cell lines in
these two cell line models.
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Fig. 6 Synergistic effect of third-generation EGFR-TKI combined with an Akt inhibitor in T790M-mutated EGFR-TKI-resistant PC9 cells. The combined
effects of the third-generation EGFR inhibitor (Osimertinib, AZD9291) targeting the T790M resistance mutation and Akt inhibitors (GSK2141795 or
AZD5363) on T790M-mutated geﬁtinib-resistant PC9-GR4 cells were assessed by a CellTiterBlue assay after 2, 4 and 6 days and b BrdU incorporation
assay performed after 5 days. Concentrations of drugs were chosen to be sub-inhibitory to explore the synergistic potential: AZD9291 0.1 and 0.2 µM;
GSK2141795 2.5 µM; and AZD5363 35 µM. All experiments were conducted in 7 replicates (a), or quadruplicates (b), and results are shown as mean± SD.
Asterisks indicate signiﬁcant difference in ANOVA 1-way test (p< 0.05) for the drug combination-treated cells compared to cells treated with either drug
alone. For the CellTiterBlue assay signiﬁcance differences was observed for days 4 and 6
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Synergistic growth inhibition of 11–18 resistant cell lines. The
growth inhibitory effect of the combination of geﬁtinib with
either of the two Akt inhibitors, GSK2141795 and AZD5363, on
different 11–18 resistant cell lines was evaluated using CellTi-
terBlue (Fig. 5c) and BrdU assays (Supplementary Fig. 7). A
synergistic growth inhibitory effect was observed in all of the
11–18 EGFR-TKI-resistant cell lines, but not in the parental
11–18 cell line, where the two drugs showed less effect (Fig. 5c
and Supplementary Table 4). Similar synergistic growth
inhibitory effect on the resistant cell lines was also observed at
lower more physiologic concentrations (Supplementary Fig. 8).
Western blotting demonstrated a complete inhibition of FOXO1/
3a phosphorylation only for the combination of EGFR TKI and
Akt inhibitor, whereas PRAS40 phosphorylation was also blocked
by the Akt inhibitors as single agent (Fig. 5d). Similarly to what
was observed in the PC9 panel, both Akt inhibitors led to an
increase in pAKT S473, but still completely prevented phos-
phorylation of Akt downstream targets, indicating a lack of Akt
kinase functional output.
Third-generation EGFR TKI and Akt inhibitor co-treatment.
To evaluate whether synergistic effect on growth between an
EGFR TKI and an Akt inhibitor could also be observed
when using a third-generation EGFR-TKI targeting the T790M
resistance mutation, we assessed the effects of osimertinib with
either of the Akt inhibitors, GSK2141795 and AZD5363. A strong
synergistic growth inhibition of the T790M-mutated EGFR-TKI-
resistant cell line PC9-GR4 was observed for both combinations
as determined by CellTiterBlue and BrdU incorporation assays
(Fig. 6). Further, we examined whether the combination of
osimertinib and an Akt inhibitor could delay the emergence of
resistance in the T790M-positive PC9-GR4 cells compared to the
single agents in a colony outgrowth assay. A delay of more
than 8 weeks for the combination treatment was observed
(Supplementary Fig. 9). Although slightly lower pEGFR levels
were present in the resistant compared to parental cells in the
absence of geﬁtinib, EGFR inhibition was critical for growth
suppression in these resistant cell lines, as shown by the
synergistic effect of EGFR TKI and Akt inhibitor co-treatment
studies (Figs. 3, 5–7 and Supplementary Fig. 9).
EGFR TKI and Akt inhibitor co-treatment of xenograft mice.
Next, we evaluated the antitumor activity of combined EGFR TKI
and Akt inhibitor treatment in a xenograft model. CB17 SCID
mice were subcutaneously inoculated in both ﬂanks with 1.5x106
PC9-ER cells that harbor increased pAkt and when palpable, mice
were administered erlotinib (25 µg/g bodyweight), GSK2141795
(10 µg/g bodyweight), the drug combination, or vehicle by oral
gavage 5 days a week. Weekly measurements using calipers
showed extensive growth of the vehicle-treated tumors, a
relatively modest antitumor effect of erlotinib or GSK2141795
alone, and a signiﬁcant inhibitory effect of the drug combination
(Fig. 6a). After 3 weeks of treatment, mice were killed and tumors
were resected. A signiﬁcant reduction in tumor volume was
observed between the vehicle group and the group receiving
combination therapy (p= 0.0017), while no signiﬁcant differences
were found between the control group and those treated with
erlotinib or GSK2141795 as single agents. Signiﬁcant differences
were also observed when comparing the tumors receiving the
combination therapy with those treated with erlotinib (p= 0.03)
or GSK2141795 (p= 0.0295) alone (Fig. 7b and Supplementary
Fig. 10a, b).
pAkt as a biomarker in EGFR-TKI-treated EGFR-mutant
patients. To validate the clinical relevance of our ﬁndings, we
ﬁrst evaluated pAKT S473 expression by IHC in baseline
samples of 75 EGFR-mutant NSCLC patients treated with
ﬁrst-line EGFR-TKIs (Supplementary Table 7). Importantly, the
stability of pAkt staining in IHC analysis was found to be robust
independent of ﬁxation time (Supplementary Fig. 11). pAkt
expression was determined by a weighted histoscore method
also known as the H-score37, which takes into account the
percentage of positive signal and staining intensity. To deﬁne
the optimal cut-point for pAkt H-score as a continuous variable
we applied the method of Contal and O’Quigley38 that uses
log-rank test statistic to estimate the cutpoint39. Using this
approach 62 was identiﬁed as the optimal cut-point divided
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patients into two groups: pAkt negative (histoscore< 62)
and pAkt positive (histoscore≥ 62). Eight out of 75 (11%) pre-
treatment samples were pAkt positive (Fig. 8a). PFS to EGFR-TKI
treatment was 14.5 months (95% conﬁdence interval (CI),
12.3–17.9) for pAkt negative patients vs. 6.1 months (95% CI,
2.3–15.6) for pAkt-positive patients (p= 0.0037), (hazard
ratio (HR) 0.341; 95% CI, 0.159–0.731; p= 0.0057; Fig. 8b).
Overall survival (OS) was 34.5 months (95% CI, 22.3–39.2) for
pAkt negative patients vs. 15.2 months (95% CI, 3.0–24.9) for
pAkt-positive patients (p= 0.0015), (HR 0.276; 95% CI, 0.118 to
0.646; p= 0.003; Fig. 8c). A univariate Cox proportional hazards
model for PFS and OS was ﬁtted using the following clinically
interesting variables: type of EGFR mutation, gender, smoking
history, age, brain metastases, and pAkt. Only the status of pAkt
contributed signiﬁcantly to PFS and OS. For a subpopulation of
the baseline samples where additional tissue was available we
evaluated whether pAkt expression correlated with individual
resistance mechanisms by examining the AXL, MET, Her2, and
FGFR1 expression and PIK3CA mutation status; however, no
such correlations were observed (Supplementary Table 8
and Supplementary Fig. 12) and high pAKT levels, although
infrequent, were observed across the tumors with each of these
known resistance mechanisms. These data reveal a potentially
important role for increased pAkt levels as a novel biomarker to
predict decreased initial EGFR-TKI response in patients across
the spectrum of previously established individual mechanisms of
resistance.
We next used IHC to evaluate pAkt in rebiopsy samples from
15 EGFR-mutant NSCLC patients after progression to EGFR TKI.
Nine of those 15 (60%) samples were pAkt positive (Fig. 8a
and Supplementary Table 9), compared with 11% pAkt
positive in pre-treatment samples. Representative images of
pre- and post-treatment samples stained for pAkt are depicted
in Fig. 8b. We furthermore evaluated common resistance
mechanisms to EGFR TKI in the 15 post-treatment samples,
and found that they represented a wide array of well-known
resistance mechanisms (Supplementary Table 10), including
T790M mutation, PIK3CA mutation, AXL upregulation,
MET ampliﬁcation, or upregulation and alterations in markers
of EMT, similarly to what we have observed in our wide variety of
our cell line models with acquired EGFR-TKI resistance.
Increased pAkt was observed across clinical specimens that have
various established resistance-associated alterations (e.g., T790M,
high AXL, high MET, and EMT), consistent with our
preclinical ﬁndings. Importantly, increased pAkt was identiﬁed
independent of T790M status, indicating that these alterations
are neither mutually exclusive nor exclusively coupled in these
EGFR-TKI-resistant tumors. Our ﬁndings in these clinical
samples provide evidence for a previously unappreciated
convergent role of Akt activation in acquired EGFR-TKI
resistance that is associated with otherwise diverse and
unpredictable upstream molecular events.
Discussion
NSCLC patients with activating EGFR mutations beneﬁt from
treatment with EGFR TKIs, but ultimately acquire resistance,
which limits PFS to 9–13 months and prevents long-term patient
survival2. Multiple mechanisms of acquired resistance to EGFR
TKI have been described by us and other investigators10, 12–16.
This diversity, coupled with the unpredictability, of EGFR-TKI
resistance mechanisms presents a major challenge for developing
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95% CI 0.159–0.731; p= 0.0057. Right: OS according to baseline pAKT expression for 75 patients with EGFR-mutant NSCLC treated with ﬁrst-line
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effective treatment regimens to overcome EGFR-TKI resistance.
Here, we show for the ﬁrst time (to our knowledge) that such
diversity in acquired resistance mechanisms is associated with
convergent activation of the Akt pathway in EGFR-mutant
NSCLC. Importantly, we have shown that the combination of an
EGFR TKI and an Akt inhibitor elicits synergistic growth
inhibition in vitro and signiﬁcant growth inhibition in vivo in
otherwise EGFR-TKI-resistant NSCLCs. We propose that by
speciﬁcally inhibiting Akt together with EGFR, these otherwise
diverse resistance mechanisms can be effectively controlled,
allowing for a more rational and feasible treatment strategy
to address both the molecular heterogeneity of EGFR-TKI
resistance40 and the simultaneous presence of more than one
mechanism of resistance (Supplementary Table 8) that we
now know characterizes EGFR-TKI progression in many EGFR-
mutant NSCLC patients. The therapeutic strategy identiﬁed in
our study here provides an alternative approach that may
more efﬁciently combat the profound molecular heterogeneity
that is an obstacle to the success of current treatments that seek to
block an individual upstream resistance mechanism (for instance,
an RTK) to overcome acquired EGFR-TKI resistance.
The importance of the Akt pathway in EGFR-TKI resistance
was validated in clinical samples from EGFR-mutant NSCLC
patients, where phosphorylation of Akt was observed in 60% of
tumor samples from patients after progression on EGFR TKIs,
but only in 11% of baseline samples. Positivity of pAkt in
post-progression samples was found independent of T790M
occurrence. Moreover, the presence of pAkt positivity in 8 out of
75 baseline samples correlated with signiﬁcantly worse PFS
and OS to ﬁrst-line EGFR-TKI treatment (6.1 vs. 14.5 months;
p= 0.0037 and 15.2 vs. 34.5 months; p= 0.0015, respectively).
Our clinical data provide new evidence for the potential
clinical utility of assessing pAkt levels as a molecular predictor of
EGFR-TKI response and resistance in EGFR-mutant NSCLC
patients.
Activation of the PI3K-Akt pathway has been reported in
EGFR-mutant cell lines and baseline tumors sensitive to TKIs
and some reports have associated it with intrinsic sensitivity to
ﬁrst-line treatment with EGFR TKIs28–32, 41, 42. However, our
report is the ﬁrst to highlight the importance of Akt activation in
cell lines or tumors with acquired resistance to EGFR TKIs and,
most importantly, across tumors with a multitude of previously
established resistance-promoting mechanisms.
Three EGFR inhibitors, erlotinib and geﬁtinib, and osimertinib,
and two Akt inhibitors, GSK2141795 and AZD5363, were
employed in our study to ensure the validity of the observations.
We did not attempt knock-down of Akt to verify the effect of the
Akt inhibitors, as no single probe can target all three isoforms of
Akt simultaneously due to sequence heterogeneity. GSK2141795
and AZD5363 are orally available inhibitors of Akt1-3 with
nanomolar or sub-nanomolar potency35, 43. Combined EGFR
TKI and Akt inhibitor treatment of the EGFR-TKI-resistant
NSCLC cells generally induced a complete inhibition of
phosphorylation of the two downstream targets PRAS40 and
FOXO1/3A. FOXO1/3A is a key pro-apoptotic protein, which,
upon phosphorylation by Akt, interacts with 14-3-3 in the
nucleus and is transported to the cytoplasm. Phosphorylated
FOXO1/3A cannot re-enter the nucleus to trigger transcription of
the pro-apoptotic program23. PRAS40 functions as a negative
regulator of mTORC1, which is a complex involved in protein
translation and ribosome biogenesis. Upon phosphorylation
by Akt, PRAS40 becomes inhibited and can no longer block
activation of the translational machinery and protein synthesis25.
Interestingly, both Akt inhibitors elicited a feedback
hyperphosphorylation of Akt at Ser473, as observed by other
investigators35, 36. This differs from the effect observed when
employing PI3K or mTOR inhibitors, which result in a decrease
in pAkt Ser47344–46.
Prior studies have evaluated the efﬁcacy of Akt inhibitors in a
range of cancers, where promising results had been obtained in
preclinical models using drug combinations that include Akt
inhibitors, such as AZD5363 combined with fulvestrant in
endocrine-resistant breast cancer47, and AZD5363 combined with
AZD8931, an EGFR/ErbB2/ErbB3 inhibitor, in ErbB2-ampliﬁed
breast cancer48. Enhanced tumor growth delay was also observed
for GSK2141795 in combination with a MEK inhibitor in models
of pancreatic cancer35. In the clinic, erlotinib has been combined
with the non-ATP competitive pan Akt inhibitor MK-2206 in a
phase II clinical trial enrolling advanced NSCLC patients with
either mutant or wildtype EGFR49. In contrast to our ﬁndings
reported here, the rationale for this trial was not to block
increased Akt activation present in the tumors during EGFR-TKI
treatment, as pAkt expression was not examined in these patients,
but instead to mitigate hepatocyte growth factor-mediated
resistance. In the EGFR-mutant arm of the trial, eligible
patients had earlier beneﬁted from, but since progressed on,
erlotinib as a single agent. Of 45 EGFR-mutant patients, four had
a partial response and 14 had stable disease. Importantly, the level
of pAkt was not evaluated in the patients prior to treatment, and
we have shown in our study that cell lines with high levels of
pAKT are most responsive to combined EGFR and Akt
inhibition. However, we have not evaluated resistant cell
lines with a low level of pAkt. Based on our new ﬁndings, we
hypothesize that there would be a correlation between the level of
pAKT and the efﬁcacy of the erlotinib and MK-2206 in the
patients from the study by Lara and colleagues49, but this infor-
mation has not been reported nor have pAKT levels been
examined retrospectively through molecular studies in these
tumor specimens to our knowledge. Thus, our ﬁndings now
provide the rationale to do so and pave the way for novel
biomarker-driven clinical trials testing an EGFR-TKI plus an Akt
inhibitor in appropriately selected EGFR-mutant NSCLC patients
with high pAkt tumor expression.
In conclusion, we have shown that Akt pathway activation is
commonly associated with acquired resistance to EGFR-TKI
treatment in NSCLCs harboring a diverse array of other,
previously identiﬁed resistance mechanisms. Phosphorylation of
Akt was detected in a minority of EGFR-mutant NSCLC
patients prior to EGFR-TKI therapy and predicted worse initial
EGFR-TKI response. Finally, we have demonstrated that
combined treatment with Akt and EGFR inhibitors elicited
synergistic growth inhibition in preclinical models of EGFR-TKI
resistance. Our ﬁndings reveal the unanticipated convergent
activation of, and dependence on, Akt in EGFR-TKI resistance
that emerges through a multitude of diverse upstream events.
While other studies have tested inhibitors of PI3K and/or mTOR
in EGFR-mutant NSCLC, our data provide a novel rationale for
speciﬁcally testing Akt inhibitors in combination with EGFR
TKIs in EGFR-mutant NSCLC patients that show Akt activation.
We propose that Akt inhibition, speciﬁcally, could more
uniformly enhance response and survival in patients with high
pAkt levels who are at high risk for Akt-mediated resistance, as
this distinct approach has the unique potential to combat the
otherwise profound heterogeneity of molecular resistance events
that are present in EGFR-mutant NSCLC patients with acquired
EGFR-TKI resistance to improve their outcomes.
Methods
Cell culture and antitumor agents. Parental PC9 cells were kindly provided by
F. Hoffman-La Roche Ltd (Basel, Switzerland) with the authorization of Dr.
Mayumi Ono (Kyushu University, Fukuoka, Japan). Parental 11–18 cells were
kindly provided by Dr. Mayumi Ono. All cell culture materials were obtained from
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Biological Industries (Kibbutz Beit Haemek, Israel) or Gibco Life Technologies
(Carlsbad, CA, USA). Cells were cultured in a humidiﬁed atmosphere with 5% CO2
at 37 °C in RPMI1640 + 10% fetal bovine serum (FBS), 50 µg/mL penicillin-
streptomycin and 2 mM L-Glutamine. EGFR inhibitors (erlotinib, geﬁtinib,
afatinib, dacomitinib, and osimertinib (AZD9291)) and the Akt inhibitor
AZD5363 were purchased from Selleck Chemicals (Houston, TX, USA).
The Akt inhibitor GSK2141795 (Uprosertib) was purchased from Medchemexpress
LLC (Monmouth Junction, NJ, USA). All drugs were dissolved in DMSO, aliquoted
and kept at −20 °C.
Mutation analyses. DNA was isolated from cell lines and hematoxilin/eosin
or IHC slides by standard procedures and genotyped by quantitative PCR with
speciﬁc probes (Taqman) or standard PCR followed by Sanger sequencing.
Gene expression analyses. RNA was isolated from the cell lines in accordance
with a proprietary procedure (European patent number EP1945764-B1) as
previously described50. The primer and probe sets were designed using Primer
Express 3.0 Software (Applied Biosystems, Foster City, CA, USA) according to
their Ref Seq (http://www.ncbi.nlm.nih.gov/LocusLink). Quantiﬁcation of gene
expression was performed using the ABI Prism 7900HT Sequence Detection
System (Applied Biosystems). Expression levels were calculated according to the
comparative ΔΔCt method. Commercial RNA controls were used as calibrators
(Liver and Lung; Stratagene, La Jolla, CA, USA). For each cell line, three
independent experiments were performed.
Western blotting. Cells were washed in ice-cold tris buffered saline (TBS), spun
down and lysed in radioimmunoprecipitation assay buffer (10 mM Tris HCl, pH 8,
5 mM Na2EDTA, pH 8, 1% NP-40, 0.5% sodium dioxycholate, 0.1% SDS), both
containing protease and phosphatase inhibitors (Complete Mini PhosphoSTOP,
Roche, Basel, Switzerland). Protein concentrations were determined by Pierce BCA
Protein Assay (Thermo Fisher Scientiﬁc, Rockford, IL, USA) according to the
manufacturer’s protocol. 5–40 μg protein was resolved on 4–12% RunBlue
SDS-PAGE gels (Expedeon, San Diego, CA, USA), transferred onto PVDF
membrane (GE Healthcare Life Sciences, Buckinghamshire, UK), blocked and
then incubated with primary monoclonal antibodies ON at 4 °C. Following, the
membranes were incubated with goat anti-rabbit, goat anti-mouse (#P0448,
#P0447, Dako, Glostrup, Denmark) or donkey anti-goat (#SC-2020, Santa Cruz
Biotechnology, Heidelberg, Germany) HRP-conjugated secondary antibodies in
1:5000 dilution for 1 h at room temperature (RT). The immune reactive bands
were visualized by Amersham ECL Prime Western Blotting Detecting Reagent
(GE Healthcare Life Sciences) and exposed to CL-Xposure ﬁlm (Thermo Fisher
Scientiﬁc).
Immunohistochemistry. IHC was performed on 5 μm sections using an auto-
mated immunostainer (Ventana BenchMark ULTRA, Ventana Medical Systems,
Oro Valley, AZ, USA) and protein expression was quantiﬁed using the histoscore
method as previously described51. The following antibodies were used: AXL
(Cell Signaling Technology, Leiden, The Netherlands, #8661, dilution 1:100),
pAkt (Cell Signaling Technology, #4060, dilution 1:50), phospho-PRAS40
(Cell Signaling Technology, #2997, dilution 1:100), E-cadherin (Roche
#5973872001, RTU), β-catenin (Roche #5269016001, RTU), vimentin (Roche
#5278139001, RTU), and N-cadherin (Abcam, Cambridge, UK, #ab18203, dilution
1:100).
Cell growth and apoptosis assays. Cells were seeded at 4000 cells per well in 96-
well plates, allowed to attach for 24 h and treated for 72 h with drug. After treat-
ment, cells were incubated with medium containing MTT (0.75 mg/mL in med-
ium) for 1 h at 37 °C. Culture medium with MTT was then removed and formazan
crystals dissolved in 100 µL DMSO (Sigma-Aldrich, St. Louis, MO, USA). Cell
numbers were estimated by measuring the absorbance at 495 nm using a micro-
plate reader (BioWhittaker, Walkersville, MD, USA).
For drug combination experiments, 10,000 cells per well were seeded in 24-well
plates and left to attach for 6 h before drugs or vehicle were added; then grown at
37 °C. Cell viability was quantiﬁed by crystal violet staining or by CellTiterBlue
(Promega, WI, USA) and cell proliferation was evaluated by BrdU incorporation
using the BrdU Cell Proliferation Assay Kit (Cell Signaling Technology, Beverly,
MA, USA), according to the manufacturer´s instructions. Crystal violet assay was
performed by adding staining solution for 5 min at RT, washing cells twice in H2O,
redissolving in
Na-citrate buffer (29.41 g Na-citrate in 50% EtOH) and measuring the absorbance
at 570 nm. Apoptosis was assessed using the Cell Death Detection ELISAPlus kit
(Roche, Basel, Switzerland) according to the manufacturer’s instructions. Colony
outgrowth assay was performed as described in Tricker et al. (2015)52.
SILAC labeling. Cells were propagated in RPMI1640 (BioNordika, Herlev,
Denmark) supplemented with 580 mg/L-glutamine and 200 mg/L proline and 10%
dialyzed FBS (Gibco, Life Technologies, Carlsbad, CA, USA). PC9-ER cells were
propagated in “heavy” media containing 75 mg/L 13C6-Lys and 28 mg/L 13C6-Arg
(Cambridge Isotope Laboratories, Tewksbury, MA, USA), and PC9 cells were
propagated in “light” medium containing 75 mg/L 12C6-Lys and 28 mg/L 12C6-Arg
(Sigma-Aldrich). Cells were propagated for six passages in SILAC media and
harvested to ascertain complete isotope incorporation.
Cell harvest for mass spectrometry. All cells were harvested at 80% conﬂuence.
Cells were washed twice with ice-cold TBS and lyzed with ice-cold 0.1 M Na2CO3
pH 11 lysis buffer containing 1 mM activated sodium pervanadate and
protease (Complete Mini EDTA-free, Roche, Basel, Switzerland) and phosphatase
(Complete Mini PhosSTOP, Roche, Basel, Switzerland) inhibitors. Cell scrapers
were used not to damage extracellular membrane proteins. The lysate was adjusted
to 1 mM MgCl2 and 3 µL benzonase (Sigma-Aldrich) was added and samples
were left on ice for 15 min to degrade RNA and DNA. Lysates were now
homogenized using a Branson soniﬁer 250, 2 × 30 s, output 10, output control 2.5.
The lysates were then centrifuged at 100,000×g for 45 min at 4 °C in a Sorvall
RC M150 GX ultracentrifuge to separate soluble proteins (supernatant)
from membraneous proteins (pellet). The pellets were washed with 0.5 M
triethylammonium bicarbonate (TEAB) followed by 0.05 M TEAB to remove
soluble protein contamination.
Protein puriﬁcation and digestion. The supernatant proteins were precipitated
by adding four volumes of ice cold acetone and left at −20 °C followed by
centrifugation at 7000×g for 15 min. The pellets containing soluble proteins
were then dissolved in 8M urea and incubated to fully dissolve protein clusters.
Protein concentrations were determined by the Bio-Rad Protein Assay before
proteins were reduced by 20 mM dithiothreitol for 45 min and subsequently
alkylated by 40 mM iodoacetamide for 45 min in the dark. Samples were then
digested with Lys-C (Sigma-Aldrich) 1 µg enzyme/50 µg protein for 5 h at RT.
Samples were diluted eight times with 0.1 M ammonium bicarbonate and digested
with trypsin (1 µg enzyme/100 µg peptide) at 37 °C. Samples were acidiﬁed to 0.1%
triﬂuoroacetic acid (TFA) and centrifuged at 15,000×g for 10 min to pellet insoluble
materials such as lipids, and the supernatant was kept for further analysis. The
membrane proteins were dissolved in 8M urea, reduced and alkylated as stated
above before 0.5 µL Sialidase A (Europa Bioproducts, Cambridge, UK) and 1 µL
PNGase F (Sigma-Aldrich) was added at 37 °C to remove extracellular glycan
structures. Then, samples were treated with Lys-C and trypsin as described above.
Digested peptides were desalted on in-house packed stage tip columns composed of
two C18 membrane disks (Empore 3M, Bellefonte, USA) and porous R2/R3
reverse-phase resins (Applied Biosystems). In brief, samples were acidiﬁed to pH
~2 before peptides were applied to 0.1% TFA pre-equilibrated columns, washed
with 0.1% TFA and eluted using 70% ACN, 0.1% TFA.
HILIC fractionation. Samples were adjusted to ~40 μL of 90% ACN, 0.1% TFA by
ﬁrst dissolving it in 0.4 μL of 10% TFA, then adding 3.6 μL of H2O, and ﬁnally
adding 36 μL of ACN. The samples were injected onto an in-house packed TSKgel
Amide-80 HILIC 320 μm× 170mm capillary HPLC column using an Agilent
1200 capillary HPLC system. The peptides were eluted using a gradient from 90%
ACN, 0.1% TFA to 60% ACN, 0.1% TFA for over 46 min at a ﬂow rate of 6 μL/min.
The fractions were automatically collected in a microwell plate at 1 min
intervals after UV detection at 210 nm, and the fractions were pooled according to
the UV detection to a total of 10 fractions. The fractions were dried by vacuum
centrifugation. Prior to LC–MS/MS the samples were redissolved in 0.5 μL of 100%
formic acid (FA) and diluted with H2O to 5.5 μL. A total of 5 μL of each fraction
were analyzed by reverse-phase nanoLC–MS/MS.
NanoLC–MS/MS and data analysis. The peptides were loaded onto an
Easy-nanoLC (Thermo Fisher Scientiﬁc) coupled to an Orbitrap FusionTM
TribridTM mass spectrometer (Thermo Fisher Scientiﬁc). Peptides were loaded
onto a pre-column (2 cm Reprosil—Pur C18 AQ 5 µm RP material (Dr. Maisch,
Ammerbuch-Entrigen, Germany)) using the EASY-LC system and eluted
directly onto a 20 cm-long fused silica capillary column (75 µm ID) packed with
Reprosil—Pur C18 AQ 3 µm RP material. The peptides were separated using a
gradient from 0–34% B (A buffer: 0.1 % FA; B buffer: 90% ACN/0.1% FA) at a
ﬂow rate of 250 nL/min over 30–90 min depending on the UV trace of the
HILIC fractions. Peptides (m/z 400–1400) were analyzed in full MS mode using a
resolution of 120.000 FWHM at 200 m/z and the peptides were selected and
fragmented using high-energy collisional dissociation (HCD) and the fragment
ions were recorded in the LTQ with low resolution (rapid scan rate). A maximum
of 3 s were allowed between each MS and for MSMS the ion ﬁlling time was set to
35 ms and an AGC target value of 2E4 ions. The mass spectrometry data were
processed using Proteome Discoverer software v1.4 (Thermo Scientiﬁc), and the
raw data were searched in the Swissprot and Uniprot databases using the Mascot
and SEQUEST search algorithms. Quantitation using SILAC was performed in
Proteome Discoverer v 1.4 using the SILAC Quantitation node.
We calculated the average of the triplicate ratios for each protein and selected
those that fulﬁlled two criteria. First, the average ratio should be ≥2-fold
differentially expressed, and second, at least two of the triplicate ratios should be
≥2-fold. We then eliminated the cytoplasmatic and membrane proteins that were
only up or downregulated in the membrane or cytoplasmic fraction, respectively.
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Ingenuity Pathway Analysis software (Qiagen, Redwood City, CA, USA) was used
for classifying proteins in functional groups.
Mice xenograft study. All animal experiments were approved by The
Experimental Animal Committee of The Danish Ministry of Justice and were
performed at the animal core facility at University of Southern Denmark. Mice
were housed under pathogen-free conditions with ad libitum food and water.
Subconﬂuent PC9-ER cells (1.5 x 106) were harvested using accutase and
resuspended in a 1:1 mixture of extracellular matrix from Engelbreth-Holm-Swarm
sarcoma (Sigma-Aldrich) and RPMI1640 media, and injected subcutaneously into
16-week-old female CB17 SCID mice (Taconic, Ejby, Denmark). When tumors
reached a palpable diameter of 2–3 mm, mice were randomized into groups of n=
9 per group. Animals were euthanized if they showed any adverse signs of disease
including weight loss, paralysis, thymus dysfunction, or general discomfort.
Accordingly, eight mice were censored during the course of the study. Erlotinib
HCl was formulated at 25 µg/g bodyweight in 15% Captisol (La Jolla, CA, USA).
GSK2141795 was formulated at 10 µg/g bodyweight in DMSO. 15% Captisol was
used as vehicle, and the concentration of DMSO did not exceed 10% when
administered. Drugs were administered 5 days a week for 3 weeks by oral gavage.
Maximum volume per mouse was 200 µL. Tumor volume and bodyweight were
surveyed during the extent of the study. Tumor volume was measured with calipers
and calculated according to: tumor volume (mm3)= (length×width2)/2.
Patient samples collection. Clinical data were assessed and tumor samples
studied in accordance with an approved protocol of the institutional review board
of Germans Trias i Pujol Hospital, Badalona, Spain and de-identiﬁed for patient
conﬁdentiality.
Statistical methods. PFS and OS were estimated by the Kaplan–Meier method,
and the nonparametric log-rank test was used to evaluate differences between
groups. Cox proportional hazard regression model was applied with pAKT as
covariate, obtaining HR and their 95% CIs. Each analysis was performed with
the use of a two-sided 5% signiﬁcance level and a 95% CI. Statistical analyses
were performed using SAS version 9.3. Synergy was deﬁned as the two drugs
together having an effect greater than the sum of the two drugs separate effects
(CI<1).
Data availability. All relevant data are available from the authors upon request.
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